Selecta Biosciences is a clinical-stage biotechnology company developing an entirely new class of targeted immunotherapies and vaccines that induces an antigen-specific immune activation or antigen-specific immune tolerance.

Selecta's proprietary Synthetic Vaccine Particle (SVP™) platform creates a new paradigm in immunology, enabling completely new therapeutic applications with the potential for improved efficacy and safety profiles.

Fully synthetic self-assembling nanoparticle manufacturing offers a number of compelling benefits, including flexible modular vaccine design and reduced development cost and time. While manufacturing and regulatory processes for biologically produced immunotherapies are often complex and time consuming, Selecta's SVP™  platform can be developed and approved faster for the following reasons:

• Self-assembly technology enables SVP™ design variations that are analogous to structure–activity relation analyses used in small molecule drug discovery
• Modular building blocks enable robust and rapid product development
• Demonstrated scalability is based upon use of established pharmaceutical unit operations and processes

Selecta's SVP™ platform technology enables diverse applications and designs. The company has created two distinct approaches to induce robust antigen-specific immune responses:

targeted Synthetic Vaccine Particles (tSVP™) activate immune responses to a wide array of relevant antigens.  Depending on the particle formulation, the nanoparticles are optimized for antibody and cytolytic T-Cell responses. Selecta is developing and optimizing candidates for a variety of applications including prevention of infectious diseases, chronic infections, cancer, allergies, and respiratory diseases.  

targeted tolerogenic Synthetic Vaccine Particles (t²SVP™) and induced tolerogenic Dendritic Cells (itDC) are developed for antigen-specific immune tolerance. Examples for applications include autoimmune diseases, allergies,  transplant rejection, and orphan diseases.

Building on the company's novel approach, Selecta's product candidates have the potential to become first-in-class or best-in-class therapeutics to treat and prevent diseases. The company's lead program entered human clinical trials in 2011, and the company is committed to rapidly advancing its broad pipeline of product candidates.

Selecta Biosciences is based in Watertown, Massachusetts, USA and Moscow, Russia.